Subscribe
shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
30 October 2020AmericasMuireann Bolger

Sanofi, Regeneron prevail against Amgen at EPO

French drugmaker  Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Sanofi and Regeneron secure stay of Praluent injunction
10 February 2017   Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent injection.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Sanofi and Regeneron secure stay of Praluent injunction
10 February 2017   Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent injection.

More on this story

Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Americas
Sanofi and Regeneron secure stay of Praluent injunction
10 February 2017   Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent injection.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility